(107 days)
Not Found
No
The summary describes a 3D printable resin for dentures and its antimicrobial properties. There is no mention of AI or ML in the device description, intended use, performance studies, or key metrics.
Yes
The device is a component used for the fabrication and repair of dentures and baseplates, which are medical devices intended to replace missing teeth and provide support for surrounding tissues, thereby having a therapeutic effect on the patient's oral health and functionality. Furthermore, the resin contains an antimicrobial agent that reduces microorganisms and biofilm formation, which can be considered a therapeutic function.
No
The device is a light-curable resin intended for the fabrication and repair of full and partial removable dentures and baseplates. It is a material used for manufacturing rather than for diagnosing a condition or disease.
No
The device is a light-curable polymerizable resin, which is a physical material used in additive manufacturing, not a software program.
Based on the provided text, the Glidewell™ 3DP Denture Base Resin is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use/Indications for Use: The intended use is for the "fabrication and repair, by additive manufacturing, of full and partial removable dentures and baseplates." This describes a material used to create a physical medical device (dentures), not a device used to examine specimens derived from the human body to provide information for diagnosis, monitoring, or screening.
- Device Description: The description focuses on the material properties, the manufacturing process (3D printing), and how it forms a hardened denture base. While it mentions in vitro studies related to antimicrobial properties, these studies are evaluating the material's effect on microorganisms on the material itself, not analyzing human specimens.
- Lack of IVD Characteristics: The text does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Providing diagnostic information
- Measuring analytes in a specimen
- Use in a laboratory setting for diagnostic purposes
The in vitro studies mentioned are related to the material's performance and safety (specifically its antimicrobial properties), which are relevant for a medical device intended for oral use, but they do not classify the device itself as an IVD.
N/A
Intended Use / Indications for Use
Glidewell™ 3DP Denture Base Resin is a light-curable polymerizable resin intended to be used in conjunction with extraoral curing light equipment. Glidewell™ 3DP Denture Base Resin is indicated for the fabrication and repair, by additive manufacturing, of full and partial removable dentures and baseplates.
Product codes
EBI
Device Description
Glidewell™ 3DP Denture Base Resin, is a light-curable resin intended to be used in conjunction with extraoral curing light equipment. Glidewell™ 3DP Denture Base Resin is indicated for the fabrication and repair, by additive manufacturing, of full and partial removable dentures and baseplates. Glidewell™ 3DP Denture Base Resin, is a light-cured methacrylic material with photo initiators that form a polymer during 3D printing. Glidewell™ 3DP Denture Base Resin is printed using digital light processing (DLP). The DLP printer and resin are optimized to each other in order to achieve complete and precise printed parts. The light source provided by the DLP printer (405nm wavelength), and the post-curing light box polymerize the resin which forms a hardened denture base. Once cured, Glidewell™ 3DP Denture Base Resin has the mechanical property that meets the performance criteria for Type 4: Light-activated materials as defined in the FDA-recognized consensus standard ISO 20795-1:2013 Dentistry - Base polymers - Part 1: Denture base polymers, including flexural strength, flexural modulus, water sorption and water solubility.
The subject device, Glidewell™ 3DP Denture Base Resin, has the same formulation and manufacturing process as the predicate device, Glidewell™ 3DP Denture Base Resin (K213765), which contains silver sodium hydrogen zirconium phosphate. In vitro studies on the subject device, Glidewell™ 3DP Denture Base Resin, demonstrated a reduction in the following microorganisms:
Microorganisms Susceptible to Glidewell™ 3DP Denture Base Resin
Streptococcus mutans
Streptococcus mitis
Staphylococcus aureus
Escherichia coli
Klebsiella pneumonia
Candida albicans
Candida glabrata
Candida tropicalis
MRSA (Methicillin Resistant Staphylococcus aureus)
VRE (Vancomycin Resistant Enterococcus)
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
In vitro studies were conducted to evaluate the activity of the incorporated antimicrobial agent, silver sodium hydrogen zirconium phosphate, in the subject device, Glidewell™ 3DP Denture Base Resin. The antimicrobial tests conducted were to assess the effectiveness of the subject device on reduction of selected microorganisms on surface contact and reduction of biofilm formation and build up.
Antimicrobial contact tests per ASTM E2180-07:
- Microorganisms: Streptococcus mutans, Streptococcus mitis, Staphylococcus aureus, Escherichia coli, Klebsiella pneumonia, Candida albicans, Candida glabrata, Candida tropicalis, MRSA (Methicillin Resistant Staphylococcus aureus), VRE (Vancomycin Resistant Enterococcus).
- Key results: The subject device reduced the viable count of all tested microorganisms by more than 99.9% compared to control samples after 24 hours of contact.
Long-term antimicrobial effect tests under accelerated aging conditions (simulating 1, 1.5, 2, 2.5, and 3 years) per ASTM E2180-07 and ASTM F1980-16, and real-time aging test over 6 months:
- Microorganisms: Streptococcus mutans, Candida albicans.
- Key results: The >99.9% reduction level was maintained under accelerated aging condition equivalent to 3 years. Real-time tests up to 6 months showed significantly higher reduction levels compared to controls.
Long-term Antibiofilm test per modified ASTM E2647-13:
- Microorganisms: Streptococcus mutans, Candida albicans.
- Key results: The subject device prevented biofilm formation and growth with a reduction rate of over 90% for S. mutans and over 70% for C. albicans.
Clinical studies have not been conducted to demonstrate that the presence of silver sodium hydrogen zirconium phosphate in Glidewell™ 3DP Denture Base Resin results in improved clinical outcomes.
Printer validation, including printing accuracy and printing orientation validation, has been performed to add an additional compatible printer model, Asiga PRO 4K, to the list of compatible printers on the device labeling.
Key Metrics
- Reduced the viable count of all the tested microorganisms by more than 99.9% as compared to the control samples of regular denture without antimicrobial agent after 24 hours of contact.
- Long-term antimicrobial test results under accelerated aging condition equivalent to 3 years of 'real-use' show the reduction of the viable counts of the tested microorganisms (S. mutans and C. albicans) maintained the >99.9% level as compared to the control samples of regular denture without antimicrobial agent.
- Long-term antibiofilm test results show that the subject device Glidewell™ 3DP Denture Base Resin, prevented the biofilm formation and growth of the tested microorganisms (S. mutans and C. albicans) with a reduction rate of over 90% for S. mutans and over 70% for C. albicans.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 872.3760 Denture relining, repairing, or rebasing resin.
(a)
Identification. A denture relining, repairing, or rebasing resin is a device composed of materials such as methylmethacrylate, intended to reline a denture surface that contacts tissue, to repair a fractured denture, or to form a new denture base. This device is not available for over-the-counter (OTC) use.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA acronym along with the full name of the agency on the right. The FDA part of the logo is in blue, with the acronym in a square and the full name, "U.S. Food & Drug Administration," written out next to it.
September 12, 2024
Prismatik Dentalcraft, Inc. Li Jiahe Regulatory Affairs Specialist, Principal 2144 Michelson Drive Irvine. California 92612
Re: K241493
Trade/Device Name: Glidewell™ 3DP Denture Base Resin Regulation Number: 21 CFR 872.3760 Regulation Name: Denture Relining, Repairing, Or Rebasing Resin Regulatory Class: Class II Product Code: EBI Dated: August 14, 2024 Received: August 14, 2024
Dear Li Jiahe:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory
2
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Michael E. Adjodha -S
Michael E. Adjodha, MChE, RAC, CQIA Assistant Director DHT1B: Division of Dental and ENT Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
Submission Number (if known)
Device Name
Glidewell™ 3DP Denture Base Resin
Indications for Use (Describe)
Glidewell™ 3DP Denture Base Resin is a light-curable polymerizable resin intended to be used in conjunction with extraoral curing light equipment. Glidewell™ 3DP Denture Base Resin is indicated for the fabrication and repair, by additive manufacturing, of full and partial removable dentures and baseplates.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
K241493
510(k) Summary
Date Prepared: August 12, 2024
Contact Details (21 CFR 807.92(a)(1))
Applicant Name: Prismatik Dentalcraft, Inc. Applicant Address: 2144 Michelson Drive Irvine CA 92612 United States Applicant Contact: Jiahe Li, Regulatory Affairs Specialist, Principal Applicant Contact Email: jiahe.li@glidewelldental.com Applicant Contact Telephone: 949-222-3516 Secondary Contact: So Hyun (Hannah) Park, Regulatory Affairs Manager Secondary Contact Email: so.park@glidewelldental.com Secondary Contact Phone: 949-863-5479
Device Name (21 CFR 807.92(a)(2))
Device Trade Name: Glidewell™ 3DP Denture Base Resin Common Name: Denture Base Resin Classification Name: Denture relining, repairing, or rebasing resin Regulation Number: 872.3760 Product Code: EBI
Legally Marketed Predicate Device (21 CFR 807.92(a)(3))
Predicate 510(k) #: K213765 Predicate Trade Name: Glidewell™ 3DP Denture Base Resin Product Code: EBI
Device Description Summary (21 CFR 807.92(a)(4))
Glidewell™ 3DP Denture Base Resin, is a light-curable resin intended to be used in conjunction with extraoral curing light equipment. Glidewell™ 3DP Denture Base Resin is Prismatik Dentalcraft, Inc. 510(k) Notification Glidewell™ 3DP Denture Base Resin August 2024
5
indicated for the fabrication and repair, by additive manufacturing, of full and partial removable dentures and baseplates. Glidewell™ 3DP Denture Base Resin, is a light-cured methacrylic material with photo initiators that form a polymer during 3D printing. Glidewell™ 3DP Denture Base Resin is printed using digital light processing (DLP). The DLP printer and resin are optimized to each other in order to achieve complete and precise printed parts. The light source provided by the DLP printer (405nm wavelength), and the post-curing light box polymerize the resin which forms a hardened denture base. Once cured, Glidewell™ 3DP Denture Base Resin has the mechanical property that meets the performance criteria for Type 4: Light-activated materials as defined in the FDA-recognized consensus standard ISO 20795-1:2013 Dentistry - Base polymers - Part 1: Denture base polymers, including flexural strength, flexural modulus, water sorption and water solubility.
The subject device, Glidewell™ 3DP Denture Base Resin, has the same formulation and manufacturing process as the predicate device, Glidewell™ 3DP Denture Base Resin (K213765), which contains silver sodium hydrogen zirconium phosphate. In vitro studies on the subject device, Glidewell™ 3DP Denture Base Resin, demonstrated a reduction in the following microorganisms:
| Microorganisms Susceptible to Glidewell™ 3DP Denture |
|---|
| Base Resin |
| Streptococcus mutans |
| Streptococcus mitis |
| Staphylococcus aureus |
| Escherichia coli |
| Klebsiella pneumonia |
| Candida albicans |
| Candida glabrata |
| Candida tropicalis |
| MRSA (Methicillin Resistant Staphylococcus aureus) |
| VRE (Vancomycin Resistant Enterococcus) |
Intended Use/Indications for Use (21 CFR 807.92(a)(5))
Glidewell™ 3DP Denture Base Resin is a light-curable resin intended to be used in conjunction with extraoral curing light equipment. Glidewell™ 3DP Denture Base Resin is indicated for the fabrication and repair, by additive manufacturing, of full and partial removable dentures and baseplates.
Indications for Use Comparison (21 CFR 807.92(a)(5))
The subject device, Glidewell™ 3DP Denture Base Resin, has the same indications for use, as the predicate device, Glidewell™ 3DP Denture Base Resin (K213765).
Technological Comparison (21 CFR 807.92(a)(6))
The subject device, Glidewell™ 3DP Denture Base Resin, has the same design as the as the predicate device. Glidewell™ 3DP Denture Base Resin (K213765). The material composition and
6
principle of operation are the same, thus the same technological characteristics regarding physical performance.
The formulation of the Glidewell™ 3DP Denture Base Resin contains silver sodium hydrogen zirconium phosphate as the antimicrobial agent. The silver containing filler is known to exhibit antimicrobial action against bacteria and fungi. This submission includes additional in vitro testing data on the antimicrobial action of the Glidewell™ 3DP Denture Base Resin regarding the common bacteria and fungi strains tested. Clinical studies have not been conducted to demonstrate that the presence of silver sodium hydrogen zirconium phosphate in Glidewell™ 3DP Denture Base Resin results in improved clinical outcomes.
| Attributes | Subject Device | Predicate Device | Comparison | |
|---|---|---|---|---|
| Device Name | Glidewell™ 3DP Denture | |||
| Base Resin | Glidewell™ 3DP Denture | |||
| Base Resin | ||||
| (K213765) | N/A | |||
| 510(k) | TBD | N/A | N/A | |
| Regulation | 21 CFR 872.3760 | 21 CFR 872.3760 | Same | |
| Product Code | EBI | EBI | Same | |
| Classification | Class II | Class II | Same | |
| Manufacturer | Prismatik Dentalcraft, Inc. | Prismatik Dentalcraft, Inc. | Same | |
| Intended Use/ | ||||
| Indications for Use | Glidewell™ 3DP Denture | |||
| Base Resin is a light-curable | ||||
| polymerizable resin intended | ||||
| to be used in conjunction with | ||||
| extraoral curing light | ||||
| equipment. Glidewell™ 3DP | ||||
| Denture Base Resin is | ||||
| indicated for the fabrication | ||||
| and repair, by additive | ||||
| manufacturing, of full and | ||||
| partial removable dentures | ||||
| and baseplates. | Glidewell™ 3DP Denture | |||
| Base Resin is a light-curable | ||||
| polymerizable resin intended | ||||
| to be used in conjunction with | ||||
| extraoral curing light | ||||
| equipment. Glidewell™ 3DP | ||||
| Denture Base Resin is | ||||
| indicated for the fabrication | ||||
| and repair, by additive | ||||
| manufacturing, of full and | ||||
| partial removable dentures | ||||
| and baseplates. | Same | |||
| Prescription Device | Yes | Yes | Same | |
| Design Characteristic | Material | |||
| Composition | Methacrylate/dimethacrylate- | |||
| based resin with photo- | ||||
| initiator, stabilizer, fillers and | ||||
| pigments. | Methacrylate/dimethacrylate- | |||
| based resin with photo- | ||||
| initiator, stabilizer, fillers and | ||||
| pigments. | ||||
| Additive | ||||
| Manufacturing | DLP printers utilizing | |||
| wavelengths of 405nm. | DLP printers utilizing | |||
| wavelengths of 405nm. | Same. Additional Asiga | |||
| printer model within the | ||||
| compatible printer type has | ||||
| been validated for the | ||||
| subject device. | ||||
| Principle of | ||||
| Operation | Light-cured denture base | |||
| resin 3D printed using digital | ||||
| light processing (DLP) | ||||
| technology, which involves | ||||
| the light-mediated conversion | ||||
| of a liquid resin containing | Light-cured denture base | |||
| resin 3D printed using digital | ||||
| light processing (DLP) | ||||
| technology, which involves | ||||
| the light-mediated conversion | ||||
| of a liquid resin containing | Same | |||
| Attributes | Subject Device | Predicate Device | Comparison | |
| Performance | ||||
| Testing | monomer and oligomer | |||
| photopolymers to a solid | ||||
| object with the desired | ||||
| physical properties for | ||||
| removable dentures and | ||||
| baseplates. | ||||
| Meets the performance | ||||
| standards for Type 4 denture | ||||
| base polymer per ISO 20795- | ||||
| 1:2013. | ||||
| In vitro antimicrobial | ||||
| testing conducted per ASTM | ||||
| E2180-07 and ASTM E2647- | ||||
| 13 (modified method) on | ||||
| Streptococcus mutans Streptococcus mitis Staphylococcus | ||||
| aureus Escherichia coli Klebsiella pneumonia Candida albicans Candida glabrata Candida tropicalis MRSA (Methicillin | ||||
| Resistant | ||||
| Staphylococcus | ||||
| aureus) VRE (Vancomycin | ||||
| Resistant | ||||
| Enterococcus) | monomer and oligomer | |||
| photopolymers to a solid | ||||
| object with the desired | ||||
| physical properties for | ||||
| removable dentures and | ||||
| baseplates. | ||||
| Meets the performance | ||||
| standards for Type 4 denture | ||||
| base polymer per ISO 20795- | ||||
| 1:2013. | Same physical performance. | |||
| The subject device included | ||||
| additional in vitro testing | ||||
| data on the antimicrobial | ||||
| action of the Glidewell™ | ||||
| 3DP Denture Base Resin | ||||
| regarding the common | ||||
| bacteria and fungi strains | ||||
| tested. | ||||
| Sterility | Non-sterile | Non-sterile | Same | |
| Biocompatibility | Biocompatible per testing | |||
| results for all applicable end | ||||
| points per ISO 10993-1:2018 | ||||
| and ISO 7405:2018 | Biocompatible per testing | |||
| results for all applicable end | ||||
| points per ISO 10993-1:2018 | ||||
| and ISO 7405:2018 | Same |
7
Non-Clinical and/or Clinical Tests Summary & Conclusions (21 CFR 807.92(b))
In vitro studies were conducted to evaluate the activity of the incorporated antimicrobial agent, silver sodium hydrogen zirconium phosphate, in the subject device, Glidewell™ 3DP Denture Base Resin. The antimicrobial tests conducted were to assess the effectiveness of the subject device on reduction of selected microorganisms on surface contact and reduction of biofilm formation and build up. The tests conducted include the following:
8
- . Antimicrobial contact tests per ASTM E2180-07 Standard test method for determining the activity of incorporated antimicrobial agent(s) in polymeric or hydrophobic materials, 2017 were conducted on the following selected microorganisms:
- Streptococcus mutans о
- Streptococcus mitis o
- Staphylococcus aureus o
- Escherichia coli o
- Klebsiella pneumonia o
- Candida albicans O
- Candida glabrata о
- Candida tropicalis o
- MRSA (Methicillin Resistant Staphylococcus aureus) o
- VRE (Vancomycin Resistant Enterococcus) о
The in vitro antimicrobial contact test results show that the subject device, Glidewell™ 3DP Denture Base Resin, reduced the viable count of all the tested microorganisms by more than 99.9% as compared to the control samples of regular denture without antimicrobial agent after 24 hours of contact, indicating a strong bactericidal and fungicidal effect under the in vitro test conditions.
- . Long-term antimicrobial effect tests under accelerated aging conditions to simulate realtime aging for 1 year, 1.5 years, 2 years, 2.5 years, and 3 years were conducted per ASTM E2180-07 Standard Test Method for Determining the Activity of Incorporated Antimicrobial Agent(s) in Polymeric or Hydrophobic Materials and ASTM F1980-16 Standard Guide for Accelerated Aging of Sterile Barrier Systems and Medical Devices, as well as real-time aging test over 6 months. The tests were conducted on the following selected microorganisms, which are the main microorganisms that cause denture stomatitis:
- o Streptococcus mutans
- o Candida albicans
The long-term antimicrobial test results under accelerated aging condition equivalent to 3 years of 'real-use' show the reduction of the viable counts of the tested microorganisms (S. mutans and C. albicans) maintained the >99.9% level as compared to the control samples of regular denture without antimicrobial agent. In addition, the real-time antimicrobial test results up to 6 months show the reduction of the viable counts of the tested microorganisms (S. mutans and C. albicans) remained at significantly higher levels as compared to the control samples over the tested period. The test results support the longterm in vitro antimicrobial effectiveness of the subject device, Glidewell™ 3DP Denture Base Resin.
- . Long-term Antibiofilm test was performed per the modified ASTM E2647-13 Standard Test Method for Quantification of Pseudomonas aeruginosa Biofilm Grown Using Drip Flow Biofilm Reactor with Low Shear and Continuous Flow developed by Center for Biofilm Engineering, Montana State University. The ASTM E2647-13 testing method was
9
modified to better simulate the 'real-use' conditions of the denture in the patient's mouth. The test was conducted on the following selected microorganisms, which are the main organisms that cause denture stomatitis:
- o Streptococcus mutans
- o Candida albicans
The long-term antibiofilm test results show that the subject device. Glidewell™ 3DP Denture Base Resin, prevented the biofilm formation and growth of the tested microorganisms (S. mutans and C. albicans) with a reduction rate of over 90% for S. mutans and over 70% for C. albicans. The results provide further support for the long-term in vitro antimicrobial effectiveness the subject device, Glidewell™ 3DP Denture Base Resin..
Clinical studies have not been conducted to demonstrate that the presence of silver sodium hydrogen zirconium phosphate in Glidewell™ 3DP Denture Base Resin results in improved clinical outcomes.
The subject device, Glidewell™ 3DP Denture Base Resin, has identical design, including chemical composition and manufacturing process, as the predicate device, Glidewell™ 3DP Denture Base Resin (K213765). Therefore, the subject device has the same physical properties as the predicate device, and physical testing data submitted with the predicate device (K213765), including flexural strength, flexural modulus, water sorption and water solubility per ISO 20795-1: 2013 Dentistry -Base polymers Part 1: Denture base polymers, apply to the subject device. No additional physical property test is needed.
In addition, printer validation, including printing accuracy and printing orientation validation, has been performed to add an additional compatible printer model, Asiga PRO 4K, to the list of compatible printers on the device labeling.